FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048134729> ?p ?o ?g. }

• W3048134729 abstract "Immune tolerance induction (ITI) with a short-course of rituximab, methotrexate, and/or IVIG in the enzyme replacement therapy (ERT)-naïve setting has prolonged survival and improved clinical outcomes in patients with infantile Pompe disease (IPD) lacking endogenous acid-alpha glucosidase (GAA), known as cross-reactive immunologic material (CRIM)-negative. In the context of cancer therapy, rituximab administration results in sustained B-cell depletion in 83% of patients for up to 26-39 weeks with B-cell reconstitution beginning at approximately 26 weeks post-treatment. The impact of rituximab on serum immunoglobulin levels is not well studied, available data suggest that rituximab can cause persistently low immunoglobulin levels and adversely impacting vaccine responses. Data on a cohort of IPD patients who received a 4-week course of rituximab and had ≥6 months of follow-up were retrospectively studied. B-cell quantitation, immunization history, and vaccine titers after B-cell reconstitution were reviewed. Data were collected for 34 IPD patients (25 CRIM-negative and 9 CRIM-positive) with a median age at ERT initiation of 3.5 months (0.1-11.0 months). B-cell reconstitution, as measured by normalization of CD19%, was seen in all patients (n=33) at a median time of 17 weeks range (11-55 weeks) post-rituximab. All maintained normal CD19% with the longest follow-up being 248 weeks post-rituximab. 30/34 (88%) maintained negative/low anti-rhGAA antibody titers, even with complete B-cell reconstitution. Infections during immunosuppression were reported in five CRIM-negative IPD patients, all resolved satisfactorily on antibiotics. There were no serious sequelae or deaths. Of the 31 evaluable patients, 27 were up to date on age-appropriate immunizations. Vaccine titers were available for 12 patients after B-cell reconstitution and adequate humoral response was observed in all except an inadequate response to Pneumococcal vaccine (n=2). These data show the benefits of short-course prophylactic ITI in IPD both in terms of safety and efficacy. Data presented here is from youngest cohort of patients treated with rituximab and expands the evidence of its safety in the pediatric population." @default.
• W3048134729 created "2020-08-13" @default.
• W3048134729 creator A5037775852 @default.
• W3048134729 creator A5047442341 @default.
• W3048134729 creator A5048344117 @default.
• W3048134729 creator A5064611705 @default.
• W3048134729 creator A5088000199 @default.
• W3048134729 date "2020-08-06" @default.
• W3048134729 modified "2023-09-30" @default.
• W3048134729 title "Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients With Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort" @default.
• W3048134729 cites W1203865291 @default.
• W3048134729 cites W1494122660 @default.
• W3048134729 cites W1825944839 @default.
• W3048134729 cites W1965723348 @default.
• W3048134729 cites W1968634262 @default.
• W3048134729 cites W1969555423 @default.
• W3048134729 cites W2004580493 @default.
• W3048134729 cites W2018799387 @default.
• W3048134729 cites W2035578076 @default.
• W3048134729 cites W2038398254 @default.
• W3048134729 cites W2041769721 @default.
• W3048134729 cites W2045320931 @default.
• W3048134729 cites W2046672031 @default.
• W3048134729 cites W2055655054 @default.
• W3048134729 cites W2057103989 @default.
• W3048134729 cites W2058536716 @default.
• W3048134729 cites W2059446551 @default.
• W3048134729 cites W2061707320 @default.
• W3048134729 cites W2068247176 @default.
• W3048134729 cites W2076454500 @default.
• W3048134729 cites W2077409993 @default.
• W3048134729 cites W2091777991 @default.
• W3048134729 cites W2091858933 @default.
• W3048134729 cites W2099289539 @default.
• W3048134729 cites W2100199292 @default.
• W3048134729 cites W2104227037 @default.
• W3048134729 cites W2112711488 @default.
• W3048134729 cites W2127215106 @default.
• W3048134729 cites W2136550752 @default.
• W3048134729 cites W2137140783 @default.
• W3048134729 cites W2143609092 @default.
• W3048134729 cites W2147798737 @default.
• W3048134729 cites W2151988044 @default.
• W3048134729 cites W2152085236 @default.
• W3048134729 cites W2155273246 @default.
• W3048134729 cites W2168225099 @default.
• W3048134729 cites W2172232925 @default.
• W3048134729 cites W2194091471 @default.
• W3048134729 cites W2214737321 @default.
• W3048134729 cites W2293144235 @default.
• W3048134729 cites W2330829730 @default.
• W3048134729 cites W2590338062 @default.
• W3048134729 cites W2728334495 @default.
• W3048134729 cites W2746547351 @default.
• W3048134729 cites W2791329038 @default.
• W3048134729 cites W2793282584 @default.
• W3048134729 cites W2809442526 @default.
• W3048134729 cites W2885508072 @default.
• W3048134729 cites W2891145080 @default.
• W3048134729 cites W2898047885 @default.
• W3048134729 cites W2940995888 @default.
• W3048134729 cites W2944148921 @default.
• W3048134729 cites W2947475941 @default.
• W3048134729 cites W2974061697 @default.
• W3048134729 cites W4211249224 @default.
• W3048134729 cites W4247693969 @default.
• W3048134729 cites W4296259680 @default.
• W3048134729 doi "https://doi.org/10.3389/fimmu.2020.01727" @default.
• W3048134729 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7424004" @default.
• W3048134729 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32849613" @default.
• W3048134729 hasPublicationYear "2020" @default.
• W3048134729 type Work @default.
• W3048134729 sameAs 3048134729 @default.
• W3048134729 citedByCount "17" @default.
• W3048134729 countsByYear W30481347292021 @default.
• W3048134729 countsByYear W30481347292022 @default.
• W3048134729 countsByYear W30481347292023 @default.
• W3048134729 crossrefType "journal-article" @default.
• W3048134729 hasAuthorship W3048134729A5037775852 @default.
• W3048134729 hasAuthorship W3048134729A5047442341 @default.
• W3048134729 hasAuthorship W3048134729A5048344117 @default.
• W3048134729 hasAuthorship W3048134729A5064611705 @default.
• W3048134729 hasAuthorship W3048134729A5088000199 @default.
• W3048134729 hasBestOaLocation W30481347291 @default.
• W3048134729 hasConcept C126322002 @default.
• W3048134729 hasConcept C159654299 @default.
• W3048134729 hasConcept C203014093 @default.
• W3048134729 hasConcept C2780252810 @default.
• W3048134729 hasConcept C2780653079 @default.
• W3048134729 hasConcept C71924100 @default.
• W3048134729 hasConcept C90924648 @default.
• W3048134729 hasConceptScore W3048134729C126322002 @default.
• W3048134729 hasConceptScore W3048134729C159654299 @default.
• W3048134729 hasConceptScore W3048134729C203014093 @default.
• W3048134729 hasConceptScore W3048134729C2780252810 @default.
• W3048134729 hasConceptScore W3048134729C2780653079 @default.
• W3048134729 hasConceptScore W3048134729C71924100 @default.
• W3048134729 hasConceptScore W3048134729C90924648 @default.
• W3048134729 hasLocation W30481347291 @default.
• W3048134729 hasLocation W30481347292 @default.

• next